Press Release

Osmetech plc ('Osmetech' or the 'Company')

Disclosure of Significant Shareholdings

1 July 2009

Osmetech PLC (“Osmetech” or “the Company”) (AIM:OMH) announces that it was notified between 25 June 2009 and 30 June 2009 of the following changes in shareholdings of ordinary 0.1p shares pursuant to the placing announced on 25 June 2009 (the “June Placing”):

Efficacy Capital Limited (‘Efficacy’) purchased 7,617,307 shares in the Company in the June Placing increasing its total interest in Osmetech to 307,200,049 shares representing 26.63% or the current issued share capital. Efficacy’s interest is held as follows:

Registered Owner	Number of ordinary shares	% of issued share capital
Efficacy Biotech Master Fund	304,230,049	26.37%
FMG Special Opportunity Fund	2,970,000	0.26%
Total	307,200,049	26.63%

Jeffrey Taylor purchased 7,617,307 shares in the Company in the June Placing through Bankers Union Trust. Jeffrey Taylor’s total interest in Osmetech shares is now 84,069,243 shares representing 7.29% or the current issued share capital. Jeffrey Taylor’s interest is held as follows:

Registered Owner	Number of ordinary shares	% of issued share capital
Crown Taylor Money Purchase Pension Plan	64,951,936	5.63%
Bankers Union Trust	19,117,307	1.66%
Total	84,069,243	7.29%

Gartmore Investment Limited has increased its shareholding in Osmetech from 189,298,177 to 222,814,326 shares, representing 19.31% of the Company’s issued share capital.

Fund Managing Co.	Number of ordinary shares	% of issued share capital	UK Registered Owner	Beneficial Owner
Gartmore Fund Managers Limited	59,358,493	5.145%	HSBC Global Custody Nominee UK Ltd	Gartmore Fund Managers Limited A/C. Gartmore UK & Irish Smaller Companies
Gartmore Investment Limited	43,885,505	3.804%	Northtrust Nominees Limited	Strathclyde Pension Fund
Gartmore Investment Limited	103,090,283	8.936%	Vidacos Nominess Ltd A/C 2303	The Alphagen Volantis Fund Limited
Gartmore Investment Limited	16,480,045	1.429%	Gartmore Growth Opportunities	Gartmore Growth Opportunities PLC

Polar Capital Healthcare Opportunities Fund’s has not purchased additional shares in the Company in the June Placing and its total interest in Osmetech is 31,651,936, representing 2.74% of the Company’s issued share capital, which has been reduced as a result of the additional placing shares.

The total number of issued ordinary 0.1p shares is 1,153,642,510. Osmetech does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Osmetech is 1,153,642,510.

For further information:

Osmetech plc:	+44 (0) 20 7849 6027
James White, Chief Executive
David Sandilands, Finance Director

Madano Partnership:	+44 (0) 207 593 4000
Mark Way
Graham Moonie

Canaccord Adams Limited:	+44 (0) 20 7050 6500
Robert Finlay
Henry Fitzgerald-O'Connor